Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 4/2018

TUBULIN, A POSSIBLE MARKER FOR THE PROGNOSTIC STRATIFICATION AND THERAPY IN PAPILLARY THYROID CARCINOMA

DELIA CIOBANU 1,2, IRINA-DRAGA CĂRUNTU 1*, LUDMILA LOZNEANU 1,2, ELENA CORINA ANDRIESCU 1,2, LETIȚIA LEUȘTEAN 3,4, SIMONA ELIZA GIUȘCĂ 1

1.Department of Morpho-functional Sciences I, University of Medicine and Pharmacy “Grigore T. Popa”, Iași, Romania
2 .Department of Pathology, “Sf. Spiridon” County Clinical Emergency Hospital, Iași, Romania
3 .Department of Medical Specialities II, University of Medicine and Pharmacy “Grigore T. Popa”, Iași, Romania
4 .Department of Endocrinology, “Sf. Spiridon” County Clinical Emergency Hospital, Iași, Romania

Download Full Article PDF

The present study aims to analyse the expression of class III β-tubulin (TUBB3) in different histological subtypes of papillary thyroid carcinoma (PTC), its relationship with the clinico-pathological factors and the potential prognostic role in the risk stratification and therapy. We evaluated the immunohistochemical TUBB3 expression in 70 cases of sporadic PTC divided in low- and high-risk subgroups based on histological criteria. We demonstrated a significant correlation between TUBB3 expression (low and moderate versus high) and the risk subgroups and tumour relapse, respectively. No association was found between TUBB3 expression and age, gender, tumour size, tumour focality, lympho-vascular invasion, extrathyroidal extension, lymph node metastases and tumour stage. Our results sustain the potential of TUBB3 as marker for prognostic stratification. Consequently, the therapy with taxanes, anti-microtubule agents that inhibit mitosis by disrupting microtubules, could be considered in the aggressive PTC cases that need a personalized therapy.